- Bestsellers
- Alcoholism
- COVID-19
- Allergy
- Anti Fungal
- Alzheimers
- Anti Viral
- Anti-Depressants
- Anti-Inflammatory
- Antibacterial
- Antiparasitic
- Antibiotics
- Arthritis
- Asthma
- Birth Control
- Blood Pressure
- Cancer
- Cardiovascular
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Drop
- Gastro Health
- General Health
- Hair Loss
- Hepatitis C Virus (HCV)
- HIV
- Hormones
- Men's ED Packs
- Men's Health
- Mental Illness
- Motion Sickness
- Muscle Relaxant
- Pain Relief
- Parkinson’s Disease
- Veterinary Medicines
- Quit Smoking
- Vitamins
- Skin Care
- Sleeping Aids
- Weight Loss
- Women's Health
Generic Rifampin
Rifampin (rifampicin) is a bactericidal antibiotic belonging to the rifamycin class, indicated for the treatment of active tuberculosis in combination with other antituberculous agents, and for the treatment of asymptomatic Neisseria meningitidis carriers to eliminate meningococci from the nasopharynx. It may also be used in combination therapy for certain staphylococcal infections, leprosy, and other mycobacterial diseases. Rifampin acts by binding to the beta‑subunit of DNA‑dependent RNA polymerase in susceptible bacteria, inhibiting RNA synthesis and preventing bacterial replication. It is effective against both intracellular and extracellular organisms. Rifampin is never used as monotherapy for active tuberculosis due to the rapid emergence of resistance; it must always be given with at least one other agent to which the isolate is susceptible.
Usual adult dose: For the treatment of active tuberculosis, the standard oral dose is 10 mg/kg (up to a maximum of 600 mg) once daily, administered either 1 hour before or 2 hours after a meal. It is given in combination with isoniazid, pyrazinamide, and ethambutol during the initial intensive phase, followed by a continuation phase. For latent tuberculosis infection, a 4‑month regimen of rifampin 10 mg/kg (max 600 mg) once daily is an accepted alternative to 9 months of isoniazid. For meningococcal carriage elimination, the dose is 600 mg twice daily for 2 days. The 150 mg and 300 mg capsules are used to construct the appropriate weight‑based dose; 450 mg and 600 mg strengths, where available, provide more convenient once‑daily dosing for adults at the 600 mg maximum. Doses must be individualized in hepatic impairment; rifampin is contraindicated in patients with active liver disease and those who develop rifampin‑associated hepatotoxicity.
Dosage form: Oral capsules: 150 mg, 300 mg, 450 mg, and 600 mg. The 150 mg and 300 mg capsules are most commonly stocked in Canadian pharmacies. Rifampin is also available as a powder for oral suspension and as a lyophilized powder for intravenous infusion when oral administration is not possible.
Onset of action: Rapidly absorbed after oral administration; peak serum concentrations are reached within 2 to 4 hours. Sputum conversion in pulmonary tuberculosis typically occurs within the first 2 months of combination therapy; clinical improvement may be evident earlier.
Duration of action: The elimination half‑life is approximately 3 to 4 hours initially, but it shortens to about 2 hours after several weeks of therapy due to auto‑induction of hepatic microsomal enzymes. Once‑daily dosing maintains adequate inhibitory concentrations. The total treatment course for drug‑susceptible tuberculosis is usually 6 to 9 months.
Alcohol recommendation: Alcohol must be avoided during rifampin therapy. Both alcohol and rifampin are hepatically metabolized and can cause liver injury; concurrent use significantly increases the risk of hepatotoxicity. Patients should be counselled to completely abstain from alcohol for the duration of treatment and during follow‑up monitoring of liver function.
Most common side effects: Harmless orange‑red discolouration of urine, sweat, tears, saliva, and other body fluids is universal and should be described to patients in advance; soft contact lenses may be permanently stained. Gastrointestinal upset (nausea, vomiting, abdominal pain, diarrhea), headache, drowsiness, and flushing are common. Hepatotoxicity, ranging from asymptomatic transaminase elevations to severe hepatitis and fatal hepatic necrosis, is a serious risk; baseline and periodic liver function tests are mandatory. Flu‑like syndrome (fever, chills, myalgia, arthralgia) may occur with intermittent dosing or if therapy is resumed after a drug holiday; continuous daily administration minimizes this reaction. Rash, pruritus, and, rarely, severe cutaneous adverse reactions including Stevens‑Johnson syndrome have been reported. Hematologic effects include thrombocytopenia, leukopenia, hemolytic anemia, and eosinophilia. Rifampin is a potent inducer of cytochrome P450 enzymes (especially CYP3A4) and drug transporters; it reduces the efficacy of many co‑administered medications, including oral contraceptives (necessitating a non‑hormonal backup method), warfarin, antiretrovirals, anticonvulsants, and immunosuppressants. A thorough drug interaction review is required before and throughout therapy. Rifampin should be permanently discontinued if significant hepatocellular damage, severe systemic hypersensitivity, or clinically relevant hematologic toxicity develops.
Would you like to try Rifampin without a prescription?
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
